Introduction {#sec1}
============

Characterized by clonal expansion of stem cells or progenitor cells in blood tissues without differentiation, acute myeloid leukemia (AML) is considered to be a highly heterogeneous disease \[[@B1]\]. As next generation sequencing was used to discover the pathogenesis of AML at the level of genes, many biomarkers for the prognosis of AML have been found. Mutations in NPM1, IDH2, and biallelic CEBPA mutations always bring longer EFS and overall survival (OS); while FLT3-ITD positive, DNMT3A, IDH1, TET2, KRAS, KIT, TP53, PTPN11, and MLL-PTD are predictors for poor outcomes \[[@B2]\].

Growth arrest-specific 6 (GAS6) is a gene that encodes the GAS6 protein and plays an important role in cell proliferation, survival, and migration. Since Manfioletti et al. considered GAS6 a new member of vitamin K-dependent proteins and may be involved in cell growth regulation, many studies have been done to uncover its biological function \[[@B3]\]. Binding with Tyro3, Axl and Mer (TAM) receptors, GAS6 gives activation for its downstream pathways like phosphatidylinositol 3-kinase (PI3K), extracellular signal-regulated kinase, and nuclear factor κ-light-chain-enhancer of activated B cells (NF-κβ) \[[@B4]\]. There were quite a little studies confirmed that up-regulation of GAS6 will disturb those pathways and lead to incontrollable growth of body cell and finally lead to cancer \[[@B5]\]. The prognostic value of GAS6 has been found in breast cancer, lung cancer, and some other common tumors like glioblastoma and renal cell carcinoma \[[@B9]\]. GAS6 expression was detected in many cell lines of leukemia \[[@B10],[@B11]\]. In recent years, Whitman et al. found that GAS6 expression also produced an adverse effect on the outcome of AML patients. Expressing of GAS6 predicted CR failure, shorter DFS, and OS in patients only received chemotherapy \[[@B12]\]. Allo-hematopoietic stem cell transplantation (HSCT) was served as a helpful method in the recovery of AML and overcame the harmful effect of some high risk molecular biomarkers \[[@B13]\]. However, the prognostic significance of GAS6 expression level in AML patients undergoing allo-HSCT was still unknown. In the present study, we compared AML patients with different levels of GAS6 expression to find out whether GAS6 a poor prognosis factor in AML patients undergoing allo-HSCT.

Materials and methods {#sec2}
=====================

Patients {#sec2-1}
--------

We screened The Cancer Genome Atlas (<https://cancergenome.nih.gov/>) and 71 diagnosed AML patients were enrolled in the study. Expression levels of GAS6-mRNA and clinical and molecular information of those AML patients were downloaded. We selected patients according to two standards. First, patients who do not have information about their GAS6-mRNA levels were excluded. Second, patients who did not undergo the treatment of allo-HSCT were excluded. Finally, 71 AML patients were included in our study.

Event-free survival (EFS) and OS were considered as two endpoints. EFS is the time from the date of diagnosis to removal from the study due to the absence of complete remission, relapse, or death. OS is the time from the date of diagnosis to death due to any cause. Written informed consent was obtained from all patients, which was approved by the Human Research Ethics Committee of Washington University.

Statistical analysis {#sec2-2}
--------------------

We compared the different biological and clinical characters using descriptive statistics. The Mann--Whitney U test was applied to two group comparisons, and chi-square test was used to compare the rate between two groups. Survival analysis about EFS and OS rates were calculated using the Kaplan--Meier method and compared using the log-rank test. Cox proportional hazard model was used to assess the hazard ratios (HRs) associated with the prognosis. A two-sided *P*-value \<0.05 was considered statistically significant for all statistical analyses. All statistical analyses were performed by SPSS Version 20.0 software.

Results {#sec3}
=======

Comparison of clinical and molecular characteristics between different GAS6-mRNA expression levels {#sec3-1}
--------------------------------------------------------------------------------------------------

Based on the median expression level, we divided 71 AML patients into two groups (GAS6-mRNA^high^, *n=* 36; GAS-mRNA^low^, *n=* 35). Clinical and molecular characteristics of two groups are summarized in [Table 1](#T1){ref-type="table"} with the results of statistic analyses. No significant differences were found in age, gender, WBC count, and peripheral blood blasts proportion between two groups, while GAS6-mRNA^low^ group seemed to have higher BM blast percentage (*P=*0.022). GAS6-mRNA^low^ group was more commonly seen in type M5 when considered FAB classification (*P=*0.034). Karyotype and risk distribution showed that patients with GAS6-mRNA^high^ always have lower proportion of inv(16)/CBFβ-MYH11 karyotype (*P=*0.020) and the rate of Good Risk classification (*P=*0.005). When comparing some of the frequent AML mutations, no significant differences were observed in FLT3-ITD, NPM1, CEBPA, DNMT3A, IDH1, IDH2, WT1, TET2, KIT, PTPN11, and PHF6 between two groups, but there were obvious distinctions between those two groups as higher level of GAS6-mRNA brought higher RUNX1 mutations (*P=*0.003), MLL-PTD mutations (*P=*0.042), TP53 mutations (*P=*0.042), and lower NRAS/KRAS mutations (*P=*0.042). Relapse rate and HSCT types distribution did not show significant differences.

###### 

Clinical and molecular characteristics of GAS6-mRNA^high^ and GAS6-mRNA^low^ patients

  Characteristics                      GAS6-mRNA^high^ (*n=* 36)   GAS6-mRNA^low^ (*n=* 35)   *U/χ^2^*   *P*-value
  ------------------------------------ --------------------------- -------------------------- ---------- -----------
  Age/years, median (range)            53.5 (18--69)               48 (22--72)                542.5\*    0.314
  Age group/n (%)                                                                             1.610^§^   0.205
    \<60 years                         24 (66.7)                   28 (80.0)                             
    ≥60 years                          12 (33.3)                   7 (20.0)                              
  Gender/n (%)                                                                                0.010^§^   0.919
    Male                               21 (58.3)                   20 (57.1)                             
    Female                             15 (41.7)                   15 (42.9)                             
  WBC count/×10^9^/l, median (range)   23.35 (0.6--223.8)          30.9 (2.3--118.8)          544.0\*    0.323
  BM blasts/%, median (range)          62 (30--100)                77 (34--99)                431.0\*    0.022
  PB blasts/%, median (range)          60 (0--96)                  45 (4--94)                 554.5\*    0.499
  FAB subtypes/n (%)                                                                                     
    M0                                 5 (13.9)                    4 (11.8)                   0.070^§^   0.791
    M1                                 13 (36.1)                   10 (29.4)                  0.356^§^   0.551
    M2                                 10 (27.8)                   8 (23.5)                   0.165^§^   0.684
    M3                                 0 (0.0)                     1 (2.9)                    1.074^§^   0.300
    M4                                 6 (16.7)                    7 (20.6)                   0.178^§^   0.673
    M5                                 0 (0.0)                     4 (11.8)                   4.492^§^   0.034
    M6                                 1 (2.8)                     0 (0.0)                    0.958^§^   0.328
    M7                                 1 (2.8)                     0 (0.0)                    0.958^§^   0.328
  Karyotype/n (%)                                                                                        
    Normal                             18 (51.4)                   14 (40.0)                  0.921^§^   0.337
    Complex                            7 (20.0)                    4 (11.4)                   0.971^§^   0.324
    8 Trisomy                          5 (14.3)                    1 (2.9)                    2.917^§^   0.088
    inv(16)/CBFβ-MYH11                 0 (0.0)                     5 (14.3)                   5.385^§^   0.020
    11q23/MLL                          1 (2.9)                     2 (5.7)                    0.348^§^   0.555
    -7/7q-                             1 (2.9)                     2 (5.7)                    0.348^§^   0.555
    t(15;17)/PML-RARA                  0 (0.0)                     1 (2.9)                    1.014^§^   0.314
    t(9;22)/BCR-ABL1                   1 (2.9)                     1 (2.9)                    0.000^§^   1.000
    t(8;21)/RUNX1-RUNX1T1              0 (0.0)                     1 (2.9)                    1.014^§^   0.314
    Others                             2 (5.7)                     4 (11.4)                   0.729^§^   0.393
  Risk/n (%)                                                                                             
    Good                               0 (0.0)                     7 (20.0)                   7.778^§^   0.005
    Intermediate                       23 (65.7)                   17 (48.6)                  2.100^§^   0.147
    Poor                               12 (34.3)                   11 (31.4)                  0.065^§^   0.799
  *FLT3-ITD*                                                                                  0.045^§^   0.832
    Presence                           9 (25.0)                    8 (22.9)                              
    Absence                            27 (75.0)                   27 (77.1)                             
  *NPM1*                                                                                      2.911^§^   0.088
    Mutation                           6 (16.7)                    12 (34.3)                             
    Wild type                          30 (83.3)                   23 (65.7)                             
  *CEBPA*                                                                                                
    Single mutation                    2 (5.6)                     3 (8.6)                    0.247^§^   0.620
    Double mutation                    2 (5.6)                     1 (2.9)                    0.319^§^   0.572
    Wild type                          32 (88.9)                   31 (88.6)                  0.002^§^   0.966
  *DNMT3A*                                                                                    0.119^§^   0.730
    Mutation                           8 (22.2)                    9 (25.7)                              
    Wild type                          28 (77.8)                   26 (74.3)                             
  *IDH1*                                                                                      0.002^§^   0.962
    Mutation                           5 (13.9)                    5 (14.3)                              
    Wild type                          31 (86.1)                   30 (85.7)                             
  *IDH2*                                                                                      0.002^§^   0.966
    Mutation                           4 (11.1)                    4 (11.4)                              
    Wild type                          32 (88.9)                   31 (88.6)                             
  *WT1*                                                                                       0.002^§^   0.966
    Mutation                           4 (11.1)                    4 (11.4)                              
    Wild type                          32 (88.9)                   31 (88.6)                             
  *RUNX1*                                                                                     8.765^§^   0.003
    Mutation                           8 (22.2)                    0 (0.0)                               
    Wild type                          28 (77.8)                   35 (100.0)                            
  *MLL-PTD*                                                                                   4.121^§^   0.042
    Presence                           4 (11.1)                    0 (0.0)                               
    Absence                            32 (88.9)                   35 (100)                              
  *NRAS/KRAS*                                                                                 4.121^§^   0.042
    Mutation                           1 (2.8)                     6 (17.1)                              
    Wild type                          35 (97.2)                   29 (82.9)                             
  *TET2*                                                                                      1.120^§^   0.290
    Mutation                           1 (2.8)                     3 (8.6)                               
    Wild type                          35 (97.2)                   32 (91.4)                             
  *TP53*                                                                                      4.121^§^   0.042
    Mutation                           4 (11.1)                    0 (0.0)                               
    Wild type                          32 (88.9)                   35 (100.0)                            
  *KIT*                                                                                       3.222^§^   0.073
    Mutation                           0 (0.0)                     3 (8.6)                               
    Wild type                          36 (100)                    32 (91.4)                             
  *PTPN11*                                                                                    0.247^§^   0.620
    Mutation                           2 (5.6)                     3 (8.6)                               
    Wild type                          34 (94.4)                   32 (91.4)                             
  *PHF6*                                                                                      1.001^§^   0.317
    Mutation                           3 (8.3)                     1 (2.9)                               
    Wild type                          33 (91.7)                   34 (97.1)                             
  Relapse                                                                                     0.065^§^   0.799
    Yes                                24 (68.6)                   23 (65.7)                             
    No                                 11 (31.4)                   12 (34.3)                             
  HSCT                                                                                                   
    Haplo                              1 (2.8)                     1 (2.9)                    0.000^§^   0.984
    Sib allo                           16 (44.4)                   14 (40.0)                  0.144^§^   0.705
    MUD                                19 (52.8)                   20 (57.1)                  0.137^§^   0.712

Allo, allogeneic; BM, bone marrow; FAB, French American British; Haplo, haploidentical; HSCT, hematopoietic stem cell transplantation; PB, peripheral blood; MUD, matched unrelated donor; WBC, white blood cell.

\*Mann--Whitney *U* test.

§Chi-square test.

The group of patients with GAS6-mRNA^high^ has shorter EFS and OS than patients in the GAS6-mRNA^low^ group through underwent allo-HSCT treatment (*P=*0.050 for EFS, *P=*0.041 for OS, [Figure 1](#F1){ref-type="fig"}A,B).

![The influence of GAS6-mRNA expression on EFS and OS\
(**A,B**) The prognostic difference between GAS6-mRNA^high^ and GAS6-mRNA^low^ group. The group of patients with GAS6-mRNA^high^ has shorter EFS and OS than patients in the GAS6-mRNA^low^ group through underwent allo-HSCT treatment.](bsr-39-bsr20190389-g1){#F1}

Univatiate and multivariate analyses for prognostic factors {#sec3-2}
-----------------------------------------------------------

We assessed the prognostic factors of clinical and molecular characteristics by choosing expression level of GAS6-mRNA (high vs low), age (\<60 vs ≥60 years), WBC count (\<30 × 10^9^/l vs ≥30 × 10^9^/l), risk classification (poor vs non-poor), and genes with more than five mutation cases (FLT3-ITD; positive vs negative; NPM1, DNMT3A, IDH2, IDH1, RUNX1, CEBPA, WT1, PTPN11, and NRAS/KRAS; mutated vs wild) to do survival analysis. Results were shown in [Table 2](#T2){ref-type="table"}.

###### 

Univariate analysis for EFS and OS

  Variables                           EFS                    OS                             
  ----------------------------------- ---------------------- ------- ---------------------- -------
  GAS6-mRNA (high vs low)             1.727 (0.993--3.002)   0.053   1.764 (1.016--3.063)   0.044
  Age (≥60 vs \<60 years)             0.995 (0.545--1.816)   0.987   1.406 (0.769--2.571)   0.268
  WBC (≥30 vs \<30 × 10^9^/l)         1.342 (0.776--2.319)   0.293   0.986 (0.571--1.702)   0.959
  Risk (poor vs non-poor)             1.081 (0.602--1.939)   0.795   1.290 (0.719--2.313)   0.393
  *FLT3-ITD* (positive vs negative)   1.798 (0.951--3.398)   0.071   1.666 (0.884--3.139)   0.114
  *NPM1* (mutated vs wild)            0.799 (0.419--1.523)   0.495   0.805 (0.422--1.536)   0.510
  *DNMT3A* (mutated vs wild)          1.120 (0.596--2.105)   0.726   1.259 (0.668--2.374)   0.477
  *IDH2* (mutated vs wild)            0.678 (0.269--1.172)   0.411   0.995 (0.392--2.525)   0.992
  *IDH1* (mutated vs wild)            0.780 (0.351--1.736)   0.543   0.756 (0.340--1.678)   0.491
  *RUNX1* (mutated vs wild)           1.648 (0.771--3.519)   0.197   2.437 (1.127--5.270)   0.024
  *CEBPA* (mutated vs wild)           0.822 (0.326--2.075)   0.679   0.695 (0.276--1.749)   0.439
  *WT1* (mutated vs wild)             2.298 (1.021--5.173)   0.045   1.587 (0.709--3.554)   0.261
  *PTPN11* (mutated vs wild)          0.695 (0.275--1.756)   0.442   0.496 (0.195--1.258)   0.140
  *NRAS/KRAS* (mutated vs wild)       0.878 (0.347--2.219)   0.783   1.412 (0.560--3.559)   0.465

Univariate analyses suggested that high expression of GAS6-mRNA was unfavorable for OS (*P=*0.044). Referring to common genes which always present in AML patients, RUNX1 (*P=*0.024 for OS) and WT1 (*P=*0.045 for EFS) also gave negative influences.

Then we selected above-mentioned factors that had statistical significance in univariate analyses and genes confirmed to be associated with prognosis to do the multivariate COX regression analyses ([Table 3](#T3){ref-type="table"}). The results indicated that high expression of GAS6-mRNA was an independent factor for poor EFS and OS (*P=*0.029, *P=*0.025) as FLT3-ITD positive (*P=*0.029, *P=*0.030).Mutations in WT1 contributed to shorter EFS (*P=*0.014), PTPN11 mutations led to shorter OS (*P=*0.007) while NPM1 mutations made longer OS (*P=*0.019). Other factors had no association with EFS and OS.

###### 

Multivariate analysis for EFS and OS

  Variables                           EFS                    OS                              
  ----------------------------------- ---------------------- ------- ----------------------- -------
  GAS6-mRNA (high vs low)             1.890 (1.066--3.353)   0.029   1.934 (1.086--3.441)    0.025
  *FLT3-ITD* (positive vs negative)   2.382 (1.095--5.181)   0.029   2.366 (1.089--5.140)    0.030
  *NPM1* (mutated vs wild)            0.479 (0.196--1.167)   0.105   0.320 (0.124--0.827)    0.019
  *DNMT3A* (mutated vs wild)          1.276 (0.652--2.499)   0.476   1.379 (0.694--2.740)    0.359
  *IDH2* (mutated vs wild)            0.615 (0.235--1.608)   0.321   0.996 (0.380--2.607)    0.993
  *IDH1* (mutated vs wild)            1.025 (0.402--2.611)   0.959   1.170 (0.457--2.996)    0.744
  *CEBPA* (mutated vs wild)           0.606 (0.224--1.636)   0.323   0.622 (0.239--1.618)    0.330
  *WT1* (mutated vs wild)             3.107 (1.258--7.675)   0.014   1.959 (0.811--4.733)    0.135
  *PTPN11* (mutated vs wild)          2.168 (0.695--6.764)   0.183   5.053 (1.546--16.513)   0.007
  *NRAS/KRAS* (mutated vs wild)       1.311 (0.492--3.489)   0.588   0.953 (0.358--2.541)    0.924

Discussion {#sec4}
==========

Our study showed that high expression level of GAS6-mRNA has a negative effect on EFS and OS in AML patients underwent allo-HSCT treatments. Multivariate analyses also suggested that GAS6-mRNA expression level of a valuable biomarker relates to prognosis. This conclusion was in accordance with Whitman et al. whose study found that GAS6 expression caused an adverse effect on the outcome of AML patients \[[@B12]\]. For further thought, it indicated that allo-HSCT cannot overcome the harmful effect of GAS6-mRNA expression as well.

Mutations in NPM1 is a favorable risk factor, while FLT3-ITD positive and DNMT3A mutations are predictors for poor outcomes in AML patients \[[@B2]\]. In our study, univariate analyses showed that NPM1, FLT3-ITD, and DNMT3A mutations had nothing to do with EFS and OS of those patients. Multivariate analyses reached the conclusion that only the expression level of GAS6-mRNA and FLT3-ITD positive made a difference in both EFS and OS. With the ideas above, it would be reliable for us to speculate that allo-HSCT can only neutralize part of the bad effects of those traditional molecular biomarkers, but the adverse prognostic impact of GAS6-mRNA expression level still could not be reversed. Thus, the expression level of GAS6-mRNA could be a better prognostic factor for AML patients undergoing allo-HSCT compared with traditional prognostic factors.

Whitman et al. did a GAS6-associated gene expression signature and found that the overexpression of genes that relevant to cell cycle and activating of IL-8 signaling pathway were most likely to be the decisive reasons that GAS6-mRNA could have its influence on the AML patients \[[@B12]\]. Recent studies have found that GAS6/TAM interaction plays an important part not only in tumor cells for its biological functions, but also have a marked impact on tumor microenvironment and cancer metastasis \[[@B14]\]. GAS6 could promote cellular survival and down-regulate apoptotic factors \[[@B15],[@B16]\], induce cell proliferation \[[@B17]\], and enhance the migration of cancer cells \[[@B20]\]. GAS6 even exerts an autocrine activity and associates with self-sustaining \[[@B23],[@B24]\]. GAS6/TAM also changes the biological behavior of immune cells and vascular smooth muscle cells \[[@B25],[@B26]\].

The biological role of GAS6 suggested a possibility for targetted treatments. Several studies considered that specific therapy targets for Axl R428 and non-specific therapy targets for Mer shRNA might be of use in AML patients \[[@B27],[@B28]\]. These would cast new light on the treatments for AML patients with GAS6-mRNA expression.

Conclusion {#sec5}
==========

In conclusion, our study indicated that high expression of GAS6-mRNA correlates with shorter EFS and OS in AML patients with allo-HSCT treatment and it could serve as a biomarker for poor prognosis. There were several limitations in our study. The limitation of case number reduced the accuracy of our statistic process. Our study is a retrospective study, whose effectiveness is not better than a prospective study. Further studies with a larger cases number shall be done to validate our findings.
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